A guide to cell-based assays in drug discovery

©2016 Macmillan Publishers Limited, part of Springer Nature.

In a recent perspective article published on Nature Reviews Drug Discovery (link), various members of the European Cell-Based Assays Interest Group summarized limitations of traditional cell-based disease models and discuss how patient-derived cultures, induced pluripotent stem cell (iPSC) technology and 3D co-cultures, complemented by single-cell imaging, microfluidics and gene editing technologies, could improve clinical significance of  preclinical drug testing. In this view, limitations of standard cell-line screens and in vivo xenografts contributed to the failure of many drug candidates that did not show clinical efficacy:
​

---

Read More